[The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol].
Bayerdörffer
E
E
Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden.
D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005744:Gastric Acid / Q000378:metabolism*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects; D009853:Omeprazole / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole